Non-initiation of hepatitis C virus antiviral therapy in patients with human immunodeficiency virus/hepatitis C virus co-infection

Table 1 Baseline demographic and clinical characteristics of patients with human immunodeficiency virus/hepatitis C virus co-infection that did not initiate hepatitis C virus therapy

Variable	Patients (n = 171)
Patient demographics
Age (median, IQR)	46 (39, 50)
Male gender, n (%)	126 (73.7)
Race/ethnicity, n (%)	-
Caucasian	32 (18.7)
African-American	126 (73.7)
Hispanic/other	13 (7.6)
Insurance, n (%)	-
Private	23 (13.5)
Public	67 (39.2)
None	64 (37.4)
Other	17 (9.9)
HIV clinical characteristics
HIV-1 RNA (log10 copies/mL) (median, IQR)	4.3 (2.7, 5)
CD4 (cells/μL) (median, IQR)	299 (91, 517)
HAART, n (%)	125 (73.1)
Prior AIDS-defining clinical condition, n (%)	37 (21.6)
HIV risk category, n (%)1	-
MSM	41 (24)
Injection drug use	97 (56.7)
HCV clinical characteristics
HCV RNA log10 copies/mL (median, IQR)2	5.8 (5.7, 5.8)
HCV RNA log10 (IU/mL) (median, IQR)3	6.5 (6.2, 6.7)
HCV genotype, n (%)4	-
Genotype 1	157 (91.8)
Genotype 2	8 (4.7)
Genotype 3	6 (3.5)
Genotype 4	1 (0.6)

¹HIV risk categories were not mutually exclusive;

²n = 25 patients with RNA reported as copies/mL (prior to May 1, 2007);

³n = 10 patients with RNA reported as IU/mL (following to May 1, 2007);

⁴Genotypes 1 and 2 were both reported in one patient. IQR: Interquartile range; HIV: Human immuno-deficiency virus; HCV: Hepatitis C virus; HAART: Highly active antiretroviral therapy; MSM: Men who have sex with men.

Table 2 Prevalence of reasons for hepatitis C virus non-treatment in patients with human immunodeficiency virus/hepatitis C virus co-infection

	Total	Race/ethnicity
	(n = 171)	African-American(n = 126)	Caucasian(n = 32)	Hispanic/other(n = 13)	P value1
≥ 1 non-modifiable medical reason, n (%)	85 (49.7)	64 (50.8)	14 (43.8)	7 (53.8)	0.806
≥ 1 potentially modifiable medical reason, n (%)	113 (66.1)	83 (65.9)	21 (65.6)	9 (69.2)	1.000
≥ 1 non-medical reason, n (%)	113 (66.1)	85 (67.5)	21 (65.6)	7 (53.8)	0.597

¹Fisher’s exact test.

Table 3 Multivariate analyses for associations between characteristics and reasons for hepatitis C virus non-treatment

Variable	Non-modifiable medical reason	Potentially modifiable medical reason	Non-medical reason
	aOR (95%CI)	aOR (95%CI)	aOR (95%CI)
Age (yr)	1.00 (0.96-1.05)	0.93 (0.87-0.98)	0.99 (0.94-1.04)
Gender
Female	Ref	Ref	Ref
Male	1.07 (0.47-2.43)	0.77 (0.30-1.95)	1.57 (0.66-3.71)
Race/ethnicity
Caucasian	Ref	Ref	Ref
African-American	1.47 (0.57-3.80)	0.72 (0.25-2.09)	0.90 (0.32-2.52)
Hispanic/other	1.94 (0.34-11.18)	1.65 (0.14-18.83)	0.46 (0.08-2.88)
Insurance
Private	Ref	Ref	Ref
Public	1.30 (0.39-4.27)	2.27 (0.65-7.93)	0.69 (0.15-3.10)
None	0.64 (0.19-2.05)	1.13 (0.34-3.76)	0.44 (0.13-1.56)
Other	0.82 (0.32-3.13)	3.03 (0.59-15.6)	0.50 (0.09-2.68)
HIV-1 RNA log10	1.08 (0.79-1.49)	0.95 (0.67-1.34)	1.11 (0.80-1.56)
CD4	0.99 (0.99-1.00)	1.00 (0.99-1.00)	0.99 (0.99-1.00)
Prior AIDS-defining clinical condition	0.46 (0.09-2.37)	0.58 (0.10-3.28)	1.49 (0.15-14.65)

aOR: Adjusted odds ratio; HIV: Human immuno-deficiency virus; AIDS: Acquired immune deficiency syndrome.